CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...

Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot could help many cancer patients live longer.

A large-scale MIT screen of tuberculosis proteins revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease.